Bacteria have been editing their own DNA for millions of years. And now we've learned to use their trick. [1] CRISPR sequences were first discovered in the E. coli genome in 1987, but their function as an adaptive immune system against bacteriophages, or viruses, was not understood until 2007.
Pick any topic. VocaCast researches it, writes it, and reads it to you.
Bacteria have been editing their own DNA for millions of years. And now we've learned to use their trick. [1] CRISPR sequences were first discovered in the E. coli genome in 1987, but their function as an adaptive immune system against bacteriophages, or viruses, was not understood until 2007. That's the remarkable part — scientists found these repeating patterns in bacterial genomes decades before realizing what they actually did.
In its natural form, the CRISPR/Cas-9 system is an adaptive immunity mechanism used by bacteria and archaea to protect against invading viruses. When a virus attacks, bacteria don't just survive — they remember. [2] As a natural defense, bacteria use CRISPR systems to store small pieces of viral DNA, which are then used to identify and cut the DNA of an invading virus. It's like an immune system with a perfect memory. But in 2012, something shifted. [1] Researchers Jennifer Doudna and Emmanuelle Charpentier repurposed the bacterial CRISPR immune system to create a tool for making precise cuts in DNA. They transformed a bacterial defense mechanism into something far more powerful — a programmable scissors for the human genome.
The system itself is elegantly simple. [3] The CRISPR/Cas9 system consists of two main components: a Cas enzyme for cutting the target DNA sequence and a single guide RNA, or gRNA. The guide RNA directs the Cas9 enzyme to a specific target by matching a custom-made, 20-base sequence to the genomic DNA. [1] You design the guide to match the exact spot you want to edit, and it acts like a bloodhound. Once the guide finds its target, the Cas9 enzyme takes over. [4] The Cas9 enzyme is a nuclease that is activated when it binds first to a guide RNA and then to the matching genomic sequence. [5] After being guided to the correct location by the gRNA, the Cas9 enzyme creates a double-strand break in the DNA.
Now the cell's own repair machinery kicks in. This is where the real power emerges. The cell has two ways to fix broken DNA. [6] The Non-Homologous End Joining repair pathway is typically used to render genes non-functional after the DNA is cut. But there's another path. [6] The Homology-Directed Repair pathway can be exploited to insert new genes or DNA fragments into the site of the break. One disables disease genes; the other installs new ones. The promise is staggering. But turning a bacterial defense system into a reliable medical tool has proven far more complicated than those first experiments suggested.
From laboratory success to bedside reality, CRISPR therapies are now delivering what seemed impossible just years ago. The most striking evidence comes from exagamglogene autotemcel, a CRISPR-based therapy approved for sickle cell disease and beta-thalassemia. [7] This treatment has achieved a greater than 90 percent reduction in severe vaso-occlusive crises and enabled transfusion independence in patients. For people living with these blood disorders, this represents not just clinical improvement — it represents freedom from the cycle of transfusions and pain crises that have defined their lives. The therapy has now achieved regulatory clearance in multiple regions following its approval. [7]
But CRISPR's reach extends far beyond blood disorders. The first human CRISPR therapy trial for transthyretin amyloidosis utilized lipid nanoparticle, or LNP, delivery of CRISPR-Cas9. [8] This matters because amyloidosis is a rare but devastating disease where proteins misfold and accumulate in organs, and delivering CRISPR directly into the body opened an entirely new frontier in treatment. In vivo CRISPR-Cas9 gene editing via lipid nanoparticles has achieved substantial transthyretin, or TTR, protein reduction in ATTR amyloidosis patients, with clinical trial data showing greater than 90 percent mean reduction in serum TTR. [9] NTLA-2001 is one specific in vivo gene-editing therapeutic agent designed to treat ATTR amyloidosis by reducing serum TTR concentration using LNP delivery of CRISPR-Cas9. [10]
The mechanics reveal why this works. Preclinical research on mice showed greater than 97 percent knockdown of mouse TTR using CRISPR-Cas9 gene editing, with hepatocytes endocytosing the LNP as the liver is the primary site of TTR formation. [11] When researchers moved to human patients, a dose-dependent response emerged. In ATTR amyloidosis patients treated with CRISPR-Cas9 therapy, higher-dose groups experienced an 87 percent reduction in serum TTR levels, with a range of 80 to 96 percent, by day 28. [9] This precision is remarkable — physicians can titrate the dose to achieve predictable protein reduction.
Thanks for listening to this VocaCast briefing. Until next time.